BDTX · Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics Inc (BDTX)
What's happening
- BDTX is up 1.20% today, trading at $2.10. — Live quote
- Volume today (137,137) is well below its 3-month average of 997,400. (Finnhub fundamentals)
- Reports earnings on 2026-11-09, 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.17 actual vs. $-0.20 estimated (+14.7%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-10-01 (14 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $107.5M | $120.3M | $214.7M | $137.8M | $88.9M |
| P/E | -2.83 | 4.23 | 9.79 | 13.11 | 31.17 |
| Price/Book | 1.12 | 1.15 | 1.70 | 1.04 | 0.63 |
| ROE | -39.55% | 27.27% | 17.38% | 7.93% | 2.01% |
| ROA | -30.39% | 21.40% | 13.90% | 6.32% | 1.62% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-09-21; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -49.6%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on BDTX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Operating income | -$12.1M | -$11.3M | -$11.0M | -$13.4M | $54.5M | -$18.1M | -$22.1M | -$20.2M |
| Net income | -$9.9M | -$9.0M | -$8.5M | -$10.6M | $56.5M | -$15.6M | -$19.9M | -$18.2M |
| EPS (diluted) | $-0.17 | $-0.16 | $-0.15 | $-0.19 | $0.98 | $-0.28 | $-0.36 | $-0.35 |
| EPS (basic) | $-0.17 | $-0.16 | $-0.15 | $-0.19 | $1.00 | $-0.28 | $-0.36 | $-0.35 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $125.0M | $132.9M | $143.0M | $157.7M | $166.4M | $176.2M | $122.6M | $137.9M |
| Total liabilities | $28.9M | $28.6M | $30.8M | $31.6M | $33.8M | $34.7M | $39.4M | $40.5M |
| Stockholders' equity | $96.1M | $104.3M | $112.2M | $126.2M | $132.6M | $141.5M | $83.3M | $97.4M |
| Total current assets | $115.4M | $123.0M | $132.4M | $139.0M | $146.7M | $155.7M | $101.2M | $115.5M |
| Total current liabilities | $15.8M | $14.5M | $15.7M | $15.5M | $16.8M | $16.8M | $20.6M | $20.8M |
| Cash & equivalents | $19.2M | $30.1M | $21.0M | $30.9M | $30.0M | $98.4M | $36.4M | $23.4M |
| Property, plant & equipment | $310.0K | $338.0K | $365.0K | $1.1M | $1.2M | $1.3M | $1.4M | $1.5M |
| Other non-current assets | $285.0K | $29.0K | $73.0K | $117.0K | $161.0K | $205.0K | $249.0K | $293.0K |
| Accounts payable | $1.4M | $3.0M | $579.0K | $975.0K | $771.0K | $2.6M | $4.0M | $2.0M |
| Accrued liabilities | $14.4M | $11.6M | $15.2M | $14.6M | $16.0M | $14.2M | $16.6M | $18.8M |
| Common stock & paid-in capital | $8.0K | $8.0K | $8.0K | $8.0K | $7.0K | $7.0K | $7.0K | $7.0K |
| Retained earnings | -$483.7M | -$473.8M | -$464.7M | -$449.6M | -$441.1M | -$430.6M | -$487.1M | -$471.1M |
| Accumulated other comprehensive income (loss) | -$68.0K | -$36.0K | $101.0K | $142.0K | -$25.0K | -$19.0K | $24.0K | $107.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.0M | -$10.2M | -$6.8M | -$7.8M | -$9.2M | $53.4M | -$15.1M | -$11.3M |
| Investing cash flow | -$3.1M | $19.5M | -$2.9M | $8.6M | -$59.2M | $8.5M | $27.8M | $2.2M |
| Financing cash flow | $217.0K | -$185.0K | -$196.0K | $134.0K | -$116.0K | $32.0K | $291.0K | -$252.0K |
| Free cash flow | — | — | — | — | — | — | -$15.1M | -$11.3M |
| Capital expenditures | — | — | — | — | — | — | $0 | $0 |
| Share-based compensation | $1.5M | $1.4M | $1.4M | $1.7M | $1.8M | $1.7M | $1.6M | $2.0M |
| Purchases of investments | $18.1M | $0 | $35.9M | $14.9M | $89.7M | $23.5M | $3.0M | $27.9M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Operating income | $12.5M | -$78.8M | -$86.5M | -$92.8M | -$126.9M |
| Net income | $22.4M | -$69.7M | -$82.4M | -$91.2M | -$125.6M |
| EPS (diluted) | $0.39 | $-1.27 | $-1.88 | $-2.52 | $-3.47 |
| EPS (basic) | $0.39 | $-1.27 | $-1.88 | $-2.52 | $-3.47 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $143.0M | $122.6M | $158.6M | $156.3M | $247.7M |
| Total liabilities | $30.8M | $39.4M | $41.8M | $40.6M | $51.8M |
| Stockholders' equity | $112.2M | $83.3M | $116.7M | $115.7M | $195.9M |
| Total current assets | $132.4M | $101.2M | $134.0M | $127.7M | $215.7M |
| Total current liabilities | $15.7M | $20.6M | $19.6M | $15.3M | $23.6M |
| Cash & equivalents | $21.0M | $36.4M | $56.2M | $34.3M | $65.8M |
| Property, plant & equipment | $365.0K | $1.4M | $1.7M | $2.6M | $3.0M |
| Other non-current assets | $73.0K | $249.0K | $0 | $0 | $16.0K |
| Accounts payable | $579.0K | $4.0M | $2.3M | $1.9M | $4.1M |
| Accrued liabilities | $15.2M | $16.6M | $17.3M | $13.4M | $19.5M |
| Common stock & paid-in capital | $8.0K | $7.0K | $7.0K | $5.0K | $5.0K |
| Retained earnings | -$464.7M | -$487.1M | -$417.4M | -$335.0M | -$243.8M |
| Accumulated other comprehensive income (loss) | $101.0K | $24.0K | -$27.0K | -$1.8M | -$414.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | $29.6M | -$62.3M | -$66.7M | -$85.1M | -$100.1M |
| Investing cash flow | -$44.9M | $17.0M | $16.3M | $53.4M | $130.6M |
| Financing cash flow | -$146.0K | $25.5M | $71.9M | $177.0K | $729.0K |
| Free cash flow | — | -$62.3M | -$66.8M | -$85.3M | -$102.9M |
| Capital expenditures | — | $0 | $33.0K | $192.0K | $2.7M |
| Share-based compensation | $6.6M | $10.6M | $9.6M | $12.2M | $14.0M |
| Purchases of investments | $164.0M | $122.9M | $61.9M | $60.1M | $49.5M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding BDTX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-06-20 to 2026-09-18
Recent transactions
- Most recent: Behbahani Ali (Reporting person) — Grant / award of 7,707 shares on 2026-09-18.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Behbahani Ali | Reporting person | Grant / award | 2026-09-18 | 7,707 |
| Raman Prakash | Reporting person | Grant / award | 2026-09-18 | 6,801 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-18 | Behbahani Ali | Reporting person | Grant / award | 7,707 | $1.93 |
| 2026-09-18 | Raman Prakash | Reporting person | Grant / award | 6,801 | $1.93 |
| 2026-06-19 | Behbahani Ali | Reporting person | Grant / award | 8,961 | $1.66 |
| 2026-06-19 | Raman Prakash | Reporting person | Grant / award | 7,907 | $1.66 |
| 2026-03-20 | Behbahani Ali | Reporting person | Grant / award | 6,919 | $2.15 |
| 2026-03-20 | Raman Prakash | Reporting person | Grant / award | 6,105 | $2.15 |
| 2025-12-12 | Behbahani Ali | Reporting person | Grant / award | 5,208 | $2.76 |
| 2025-12-12 | Raman Prakash | Reporting person | Grant / award | 4,665 | $2.76 |
| 2025-09-19 | Behbahani Ali | Reporting person | Grant / award | 4,291 | $3.35 |
| 2025-09-19 | Raman Prakash | Reporting person | Grant / award | 3,843 | $3.35 |
| 2025-06-20 | Behbahani Ali | Reporting person | Grant / award | 6,170 | $2.33 |
| 2025-06-20 | Raman Prakash | Reporting person | Grant / award | 5,526 | $2.33 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 07:49 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-21 | 4 | 2026-09-18 | View on SEC.gov → |
| 2026-09-21 | 4 | 2026-09-18 | View on SEC.gov → |
| 2026-08-05 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-05 | 8-K | 2026-08-05 | View on SEC.gov → |
| 2026-06-29 | 4 | 2026-06-26 | View on SEC.gov → |
| 2026-06-29 | 4 | 2026-06-26 | View on SEC.gov → |
| 2026-06-29 | 4 | 2026-06-26 | View on SEC.gov → |
| 2026-06-29 | 4 | 2026-06-26 | View on SEC.gov → |
| 2026-06-29 | 4 | 2026-06-26 | View on SEC.gov → |
| 2026-06-29 | 4 | 2026-06-26 | View on SEC.gov → |
| 2026-06-29 | 8-K | 2026-06-26 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-19 | View on SEC.gov → |
Recent news
Headlines about BDTX (Black Diamond Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
We're Not Very Worried About Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Simply Wall Street · 2026-10-21 -
Black Diamond Therapeutics Stock Price Forecast. Should You Buy BDTX?
StockInvest.us · 2026-10-16 -
BDTX Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares - Next Quarter Guidance
https://www.dars.gov.et/ · 2026-10-16 -
Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?
Yahoo Finance · 2026-09-04 -
Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
Yahoo Finance · 2026-09-02 -
Black Diamond Therapeutics GAAP EPS of -$0.17 beats by $0.03
Seeking Alpha · 2026-08-05 -
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Yahoo Finance · 2026-08-05 -
Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside
Seeking Alpha · 2026-07-06
No headlines in this category right now — try “All”.